Agios Pharmaceuticals Stock Beta
| 8AP Stock | EUR 52.50 1.50 2.94% |
Agios Pharmaceuticals fundamentals help investors to digest information that contributes to Agios Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Agios Stock. The fundamental analysis module provides a way to measure Agios Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Agios Pharmaceuticals stock.
Agios |
Agios Pharmaceuticals Company Beta Analysis
Agios Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Agios Pharmaceuticals Beta | 0.92 |
Most of Agios Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Agios Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Agios Pharmaceuticals has a Beta of 0.9163. This is 6.55% higher than that of the Healthcare sector and 34.08% lower than that of the Biotechnology industry. The beta for all Germany stocks is notably lower than that of the firm.
Agios Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Agios Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Agios Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Agios Pharmaceuticals by comparing valuation metrics of similar companies.Agios Pharmaceuticals is currently under evaluation in beta category among its peers.
Agios Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Agios Pharmaceuticals is expected to follow.
Agios Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (18.34) % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 54.94 M | |||
| Shares Owned By Insiders | 1.34 % | |||
| Shares Owned By Institutions | 98.67 % | |||
| Price To Earning | (9.13) X | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 159.36 X | |||
| Revenue | 14.24 M | |||
| Gross Profit | 140.39 M | |||
| EBITDA | (380.48 M) | |||
| Net Income | (231.8 M) | |||
| Cash And Equivalents | 495.39 M | |||
| Cash Per Share | 8.43 X | |||
| Total Debt | 116.47 M | |||
| Debt To Equity | 21.80 % | |||
| Current Ratio | 5.96 X | |||
| Book Value Per Share | 19.13 X | |||
| Cash Flow From Operations | (309.48 M) | |||
| Earnings Per Share | (6.05) X | |||
| Target Price | 62.43 | |||
| Number Of Employees | 25 | |||
| Beta | 0.92 | |||
| Market Capitalization | 1.39 B | |||
| Total Asset | 1.24 B | |||
| Z Score | 6.6 | |||
| Net Asset | 1.24 B |
About Agios Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.